Gilteritinib

82 interactions 305 cited references
Also sold as: Xospata Xospata®
About Gilteritinib

Gilteritinib is used to treat a certain type of acute myeloid leukemia (AML) that has worsened or returned after treatment with other chemotherapy medications. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be neede… Read the full Gilteritinib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Mumps Virus Vaccine, Live Dengue Tetravalent Vaccine, Live Ensitrelvir Rubella Virus Vaccine, Live Measles Virus Vaccine, Live Bacillus Of Calmette And Guerin Vaccine, Live
10 Contraindicated 64 Major 8 Moderate
All (82) Contraindicated (10) Major (64) Moderate (8)

Major

Gilteritinib Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Itraconazole Sporanox Increased gilteritinib plasma concentrations Details Gilteritinib Ketoconazole Extina Increased gilteritinib exposure Details Gilteritinib Lenacapavir Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Gilteritinib Letermovir Prevymis Increased CYP3A substrate exposure Details Gilteritinib Lopinavir Increased gilteritinib plasma concentrations Details Gilteritinib Mifepristone Korlym Increased CYP3A4 substrate exposure Details Gilteritinib Nefazodone Increased gilteritinib plasma concentrations Details Gilteritinib Nelfinavir Viracept Increased gilteritinib plasma concentrations Details Gilteritinib Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Gilteritinib Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Gilteritinib Phenytoin Dilantin Reduced gilteritinib exposure Details Gilteritinib Posaconazole Noxafil Increased gilteritinib plasma concentrations Details Gilteritinib Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Gilteritinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Gilteritinib Ribociclib Kisqali Increased gilteritinib plasma concentrations Details Gilteritinib Rifampin Rifadin Reduced gilteritinib exposure Details Gilteritinib Ritonavir Norvir Increased gilteritinib plasma concentrations Details Gilteritinib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Gilteritinib Saquinavir Increased gilteritinib plasma concentrations Details Gilteritinib Sirolimus Felycin Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib St John's Wort Reduced gilteritinib exposure Details Gilteritinib Sunitinib Sutent Increased BCRP substrate exposure and increased incidence and severity of adverse reactions associated with the BCRP substrate Details Gilteritinib Tacrolimus Astagraf Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Gilteritinib Telaprevir Increased gilteritinib plasma concentrations Details Gilteritinib Telithromycin Increased gilteritinib plasma concentrations Details Gilteritinib Tolvaptan Jynarque Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Gilteritinib Vimseltinib Romvimza Increased risk of P-gp substrate exposure Details Gilteritinib Voriconazole Vfend Increased gilteritinib plasma concentrations Details Gilteritinib Ketoconazole Topical Extina® Foam Increased gilteritinib exposure Details Gilteritinib Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Gilteritinib Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Gilteritinib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details

Moderate

Gilteritinib Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Gilteritinib Kratom Increased CYP3A substrate exposure Details Gilteritinib Levacetylleucine Aqneursa Increased P-gp inhibitor exposure and an increased risk of P-gp substrate-related adverse reactions Details Gilteritinib Levothyroxine Ermeza Increased risk of hypothyroidism Details Gilteritinib Lomitapide Increased P-gp substrate exposure Details Gilteritinib Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.